Nitasha Sarswat to Biomarkers
This is a "connection" page, showing publications Nitasha Sarswat has written about Biomarkers.
Connection Strength
0.266
-
Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2026 Sep 01; 27(9):1603-1612.
Score: 0.037
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
Score: 0.037
-
Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis. Blood Adv. 2026 08 11; 10(15):5293-5307.
Score: 0.037
-
Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection. Circ Cardiovasc Imaging. 2026 Jun; 19(6):e019610.
Score: 0.037
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
Score: 0.036
-
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
Score: 0.034
-
99m Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. Muscle Nerve. 2023 Feb; 67(2):111-116.
Score: 0.029
-
Plasma Serotonin in Heart Failure: Possible Marker and Potential Treatment Target. Heart Lung Circ. 2017 May; 26(5):442-449.
Score: 0.019